MiniMed Group Inc
What Do They Do?
Sells continuous glucose monitoring sensors and integrated insulin-delivery systems to people requiring intensive insulin therapy and the healthcare professionals who prescribe them.
10-K for FY2026, filed Jun 29, 2026
How Do They Make Money?
Individuals, distributors, healthcare providers and institutions buy diabetes devices and related software; product sales are earned when goods ship or are delivered, while training and care services are earned as provided.
10-K for FY2026, filed Jun 29, 2026
-
10-K for FY2026, filed Jun 29, 2026
FY2026 revenue by product or service ↗
$3.1B
-
10-K for FY2026, filed Jun 29, 2026
$3.1B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pumps
Mix
10-K for FY2026, filed Jun 29, 2026 |
18% |
Pumps, FY2026
$546M Sources
|
Mix |
|
Consumables
Sold outright
10-K for FY2026, filed Jun 29, 2026 |
31% |
Consumables, FY2026
$956M Sources
|
Sold outright |
|
CGM
Sold outright
10-K for FY2026, filed Jun 29, 2026 |
50% |
CGM, FY2026
$1.6B Sources
|
Sold outright |
|
Other
Sold outright
|
1.5% |
Other, FY2026
$46M Sources
|
Sold outright |
Who Are Their Customers?
In the United States, it sells primarily to patients directly and also through independent distributors; elsewhere, individuals, healthcare providers and other institutions buy through country-specific processes that can include tenders and government procurement.
10-K for FY2026, filed Jun 29, 2026
Do Revenues Turn Into Profits?
No. It lost $333M in FY2026.
10-K for FY2026, filed Jun 29, 2026
−$190MView ↗
10-K for FY2026, filed Jun 29, 2026
−$333MView ↗
10-K for FY2026, filed Jun 29, 2026
−$420MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Sep 8, 2026
$0View ↗
- ▲ Now profitable
- vs −$19M in Q1 FY2026
-
Sep 1, 2026
Raised organic revenue growth guidance
Raised the outlook to approximately 10.5% from approximately 10%, including approximately 1.0 to 1.5% from the extra week.
Sources
8-K, filed Sep 1, 2026
Organic revenue growth of approximately 10.5%, which includes the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27, a raise…View ↗
Who Do They Compete With?
Competes with Beta Bionics, Dexcom, Insulet, Sequel Med Tech, Tandem Diabetes Care, Ypsomed, and Medtrum
10-K for FY2026, filed Jun 29, 2026The product lines in which we compete include the components of our AID systems, including insulin pumps like the MiniMed 780G and MiniMed…View ↗
Loading...
